This IQVIA white paper outlines a tailored, archetype‑driven approach to pharma launch investment, helping companies optimise OPEX across diverse therapeutic landscapes. It explains four launch archetypes—Share of Voice, Science‑led, Ecosystem Building and CoE‑focused—and how they guide decisions on when, where and how much to invest. With real‑world case studies and benchmarks, the paper shows how smarter, evidence‑based spending can improve launch performance, shape emerging therapy areas, and strengthen portfolio planning in increasingly complex, competitive markets.